Accelerating precision medicine of cancer with SomaScan® proteomics
Accelerating precision medicine of cancer
with SomaScan proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology — the SomaScan Platform, which measures 7,000 proteins — to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.
Efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will also be presented.
Learn about:
- Plasma protein biomarkers for predicting response to immunotherapy in metastatic melanoma
- Serum protein biomarkers for differential diagnosis of oral squamous cell carcinoma
- Plasma protein biomarkers for pancreatic cancer
- Exosome protein biomarkers for pancreatic cancer
- Urine protein biomarkers for pancreatic cancer and triple negative breast cancer
- Pre-diagnostic plasma protein biomarkers for early detection of hepatocellular cancer
Towia Libermann, PhD
Towia Libermann, PhD, is Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. He is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center and of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core.
Accelerating precision medicine of cancer with SomaScan proteomics
A presentation by Towia Libermann, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.